Abstract
‘Selecting a non-steroid anti-inflammatory drug (NSAID) for an individual patient remains more an art than a science’1. Prescribing of NSAIDs has been influenced by a lack of reliable scientific data on individual agents with respect to gastrointestinal (GI) tolerability or detrimental effects on cartilage metabolism. This has led to a number of unsubstantiated marketing claims about NSAIDs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Gottlieb NL. The art and science of non-steroidal anti-inflammatory drug selection. Semin Arthritis. 1985;15(suppl 2):1.
Furst DE. Are there differences among nonsteroidal antiinflammatory drugs? Arthritis Rheum. 1994;37:1–9.
Day RO, Graham GG, Williams KM, Brooks PM. Variability in response to NSAIDs: Fact or fiction? Drugs. 1988;36:643–51.
Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med. 1991;324:1716–25.
Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res. 1995 44:423–33.
Wiesenberg-Boettcher I, Schweizer A, Green JR, Mueller K, Maerki F, Pfeilschifter J. The pharmacological profile of COP 28238, a novel highly potent anti-inflammatory compound. Drugs Exp Clin Res. 1989;15;501–9.
Fowler PD, Shadforth MF, Crook PR, John VA. Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis. Eur J Clin Pharmacol. 1983;25:389–94.
Fowler PD, Dawes PT, John VA, Shotton PA. Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a 100 mg slow-release formulation. EurJ Clin Pharmacol. 1986;31:469–72.
Emori WE, Champion GD, Bluestone R, Paulus HE. Simultaneous pharmacokinetics of indomethacin in serum and synovial fluid. Ann Rheum Dis. 1983;32:433–5.
Gallo JM, Gall EP, Gillespie WR, Albert KS, Perrier D. Ibuprofen kinetics in plasma and synovial fluid of arthritic patients. J Clin Pharmacol. 1986;26:65–70.
Day RO, Francis H, Vial J, Geisslinger G, Williams KM. Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. J Rheumatol. 1995;22:2295–303.
Degner F, Heinzel G, Busch U. Transsynovial kinetics of meloxicam. Scand 7 Rheumatol. 1995; 98(suppl 98):121.
Kurowski M, Dunky A. Transsynovial kinetics of piroxicam in patients with rheumatoid arthritis. Eur J Clin Pharmacol. 1988;34:401–6.
Engelhardt G, Bögel R, Schnitzler C, Utzmann R. Meloxicam: Influence on arachidonic acid metabolism. In vitro findings - Part I. Biochem Pharmacol. 1996;51:21–8.
Churchill L, Graham AG, Shih C-K, Pauletti D, Farina PR, Grob PM. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharmacology. 1996;4:125–35.
Patrignani P, Panara MR, Greco A et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994;271:1705–12.
Pairet M, Engelhardt G. Differential inhibition of COX- 1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. In: Vane J, Botting J, Botting R (eds): Improved Non-steroid Anti-inflammatory Drugs — COX-2 Enzyme Inhibitors. Dordrecht/Boston/London: Kluwer Academic Publishers; 1996;103–19.
Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: A global analysis of clinical trials. Br J Rheumatol. 1996;35(1):68–77.
Lanza FL. Gastrointestinal toxicity of new NSAIDs. Am J Gastroenterol. 1993;88:1318–23.
Geis GS, Stead H, Wallemark CB, Nicholson PA. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, an interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol Suppl. 1991;28:11–14.
A report from the SPALA Project. The Design of SPALA (Safety Profile of Antirheumatics in Long-term Administration): an intensive monitoring system for NSAIDs. Eur J Clin Pharmacol. 1988;34:529–30.
Longman MJS. Anti-inflammatory drugs and the gut: ulcerative damage and protection from cancer. Proceedings of Symposium: New Insights into Anti-inflammatory Therapy and its Benefits, Cannes, October 1994. Macclesfield, UK: Adelphi Communications Ltd.
Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769–72.
Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from non aspirin non steroidal anti-inflammatory drugs. Gastroenterology. 1993;105:1978–88.
Savage RL, Moller PW, Ballantyne CL, Wells JE. Variation in the risk of peptic ulcer complications with non steroidal anti-inflammatory drug therapy. Arthritis Rheum. 1993;36:84–90.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Fenner, H. (1996). Differential target tissue presentation and COX-2/COX-1 inhibition by non-steroid anti-inflammatory drugs: a rationale for a new classification. In: Bazan, N., Botting, J., Vane, J. (eds) New Targets in Inflammation. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5386-7_11
Download citation
DOI: https://doi.org/10.1007/978-94-011-5386-7_11
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6265-7
Online ISBN: 978-94-011-5386-7
eBook Packages: Springer Book Archive